Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors.

Xuechao LiuGuangfeng WangXianglei YanHaibo QiuPing MinMiaoyi WuChunyang TangFei ZhangQiuqiong TangSaijie ZhuMiaozhen QiuWei ZhuangDouglas D FangZhou-Wei ZhouDajun YangYifan Zhai

Published in: Cell & bioscience (2019)

Collectively, our in vitro and in vivo results suggest that the therapeutic application of HQP1351 in imatinib-resistant GIST patients deserves further investigation in clinical trials.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
randomized controlled trial
stem cells
cell therapy
mesenchymal stem cells
drug delivery
combination therapy
open label
phase ii
study protocol
patient reported
wild type